Literature DB >> 1820870

Ocular distribution of cyclosporin A (Sandimmun) following systemic and topical administration to rabbits.

L Vernillet1, R L Lundh, F Acezat-Mispelter, C Goizel, H Humbert, Y Pouliquen.   

Abstract

The purpose of this study was to determine the distribution of cyclosporin A (CsA) in various ocular fluids and tissues in the rabbit by two routes of administration. CsA was administered to two groups of two rabbits either by intramuscular route at a dose of 25 mg/kg/day or by local route using eyedrops, at a dose of 10 mg/day (-2.8 mg/kg/day) for eight days. An extra animal was treated with a placebo solution in each group in order to obtain control values. Samples of blood and tears were collected throughout the 8-day treatment period. On day 9, the six animals were sacrificed and additional samples were collected from the vitreous body, the aqueous humor, the cornea and the globe. The concentrations of CsA were determined by RIA using the specific monoclonal antibody contained in the Sandimmun-kit. After administration by intramuscular route, high concentrations of CsA were detected in the blood. Within the eye, this compound was clearly detected in the tears, the cornea and the globe, and was suspected in the vitreous body and the aqueous humor. After administration by local route, using eyedrops, no CsA was detected in the blood, the vitreous body or the aqueous humor. However, despite doses ten times lower than those administered by the intramuscular route, this compound was clearly detected in the tears, the cornea and the globe of the treated eye. Moreover, similar concentrations were obtained in the untreated eye. These data reveal a real passage of CsA from the left treated eye to the right untreated eye.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1820870

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  1 in total

1.  Cyclosporin A in the ocular fluids of uveitis patients following long-term systemic administration.

Authors:  Paolo Mora; Uta Ceglarek; Francesca Manzotti; Laura Zavota; Arturo Carta; Raffaella Aldigeri; Jelka G Orsoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-06       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.